Frontiers in Neuroanatomy
2025
Wigínio Gabriel de Lira-Bandeira, Lílian Andrade Carlos de Mendonça Batista, Andréa Silva de Medeiros Bandeira et al.
4 citations
The striatum (St) integrates cognitive, motor, and limbic functions and plays a critical role in processing emotions, motivation, and rewards. It may undergo several morphophysiological changes in neuropsychiatric diseases. Depression, a complex psychiatric disorder, affects millions of people around the world and leads to an increased risk of suicide, decreased quality of life, and functional...
May 1, 2024
Banan Ramarushton
Rumination is a well-established risk factor for the onset and maintenance of depression and anxiety and has been identified as a transdiagnostic factor due to its association with multiple forms of psychopathology. A renaissance of psychedelic research shows promise in treating psychopathology with potential for acting on ruminative processes. Despite the growing interest and developments in...
Advances in experimental medicine and biology
2024
Berend Olivier, Jocelien D A Olivier
11 citations
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder, associated with substantial burden and large economical costs. Notwithstanding various conventional antidepressant treatment options, a large portion of depressed people (ca. 30%) fails to respond to first-line treatment, resulting in treatment-resistant depression (TRD). Although non-response to multiple antidepressant...
Scientific Reports
November 10, 2023
Lucas Cruz, Bheatrix Bienemann, Fernanda Palhano-Fontes et al.
3 citations
Ayahuasca is a brew with psychoactive properties that has been used as an entheogen for centuries, with more recent studies suggesting it is a promising treatment for some clinical disorders. Although there is an emerging scientific literature on its effects, to the best of our knowledge no study has explored the self-reported experiences of first-time ayahuasca users with quantitative textual...
The Maastricht Journal of Liberal Arts
September 19, 2023
Elena Gomel Cordeiro
This paper examines the possible consequences of medicalising the psychedelic Ayahuasca to be used as a treatment for depression. Through a science and technology studies (STS) understanding of the social construction of scientific facts, I consider how traditional indigenous uses of Ayahuasca are translated into Western medicine. Two special points of attention are: (1) the cultural...
Research Square (Research Square)
August 23, 2023
Lucas Villar Magalhães da Cruz, Bheatrix Bienemann Favero, Fernanda Palhano-Fontes et al.
preprint
Abstract Ayahuasca is a brew with psychoactive properties that has been used as an entheogen for centuries, with more recent studies suggesting it is a promising treatment for some clinical disorders. Although there is an emerging scientific literature on its effects, to the best of our knowledge no study has explored the self-reported experiences of first-time ayahuasca users with quantitative...
Progress in neuro-psychopharmacology & biological psychiatry
July 13, 2023
Dimitri Daldegan-Bueno, Natalia Maria Simionato, Vanessa Manchim Favaro et al.
18 citations
The psychedelic brew ayahuasca is increasingly being investigated for its therapeutic potential. Animal models are essential to investigate the pharmacological effects of ayahuasca since they can control important factors influencing it, such as the set and setting. Review and summarise data available on ayahuasca research using animal models. We systematically searched five databases (PubMed,...
Analytical and Bioanalytical Chemistry
July 1, 2023
Flávia S Zandonadi, Alex Ap Rosini Silva, Aline A S Melo et al.
9 citations
Emerging insights from metabolomic-based studies of major depression disorder (MDD) are mainly related to biochemical processes such as energy or oxidative stress, in addition to neurotransmission linked to specific metabolite intermediates. Hub metabolites represent nodes in the biochemical network playing a critical role in integrating the information flow in cells between metabolism and...
The Psychiatric clinics of North America
June 1, 2023
Shubham Kamal, Manish Kumar Jha, Rajiv Radhakrishnan
32 citations
There is increasing interest in exploring the therapeutic potential of psychedelics in treatment-resistant depression (TRD). Classic psychedelics (such as psilocybin, LSD, ayahuasca/DMT), and atypical psychedelics (such as ketamine) have been studied in TRD. The evidence for the classic psychedelics TRD is limited at the present time; early studies however show promising results. There is also...
Frontiers in Psychiatry
February 10, 2023
Muhammad Ishrat Husain, Nicole Ledwos, Elise Fellows et al.
47 citations
Introduction Current treatment options for major depressive disorder (MDD) have limited efficacy and are associated with adverse effects. Recent studies investigating the antidepressant effect of serotonergic psychedelics—also known as classic psychedelics—have promising preliminary results with large effect sizes. In this context, we conducted a review of the putative neurobiological...